19 related articles for article (PubMed ID: 38527651)
1. High-risk features associated with recurrence in stage I lung adenocarcinoma.
Fick CN; Dunne EG; Vanstraelen S; Toumbacaris N; Tan KS; Rocco G; Molena D; Huang J; Park BJ; Rekhtman N; Travis WD; Chaft JE; Bott MJ; Rusch VW; Adusumilli PS; Sihag S; Isbell JM; Jones DR
J Thorac Cardiovasc Surg; 2024 May; ():. PubMed ID: 38788834
[TBL] [Abstract][Full Text] [Related]
2. Partial Hepatectomy Promotes the Development of KRASG12V-Induced Hepatocellular Carcinoma in Zebrafish.
Zhu M; Li Y; Liu D; Gong Z
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791872
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors.
Wang X; Wang W; Zou S; Xu Z; Cao D; Zhang S; Wei M; Zhan Q; Wen C; Li F; Chen H; Fu D; Jiang L; Zhao M; Shen B
Cell Res; 2024 Jun; ():. PubMed ID: 38914844
[No Abstract] [Full Text] [Related]
4. Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features.
Cao H; Ma Z; Li Y; Zhang Y; Chen H
J Thorac Cardiovasc Surg; 2023 Dec; 166(6):e479-e499. PubMed ID: 37142051
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
Renaud S; Falcoz PE; Schaëffer M; Guenot D; Romain B; Olland A; Reeb J; Santelmo N; Chenard MP; Legrain M; Voegeli AC; Beau-Faller M; Massard G
Br J Cancer; 2015 Oct; 113(8):1206-15. PubMed ID: 26372703
[TBL] [Abstract][Full Text] [Related]
7.
Jones GD; Caso R; Tan KS; Mastrogiacomo B; Sanchez-Vega F; Liu Y; Connolly JG; Murciano-Goroff YR; Bott MJ; Adusumilli PS; Molena D; Rocco G; Rusch VW; Sihag S; Misale S; Yaeger R; Drilon A; Arbour KC; Riely GJ; Rosen N; Lito P; Zhang H; Lyden DC; Rudin CM; Jones DR; Li BT; Isbell JM
Clin Cancer Res; 2021 May; 27(9):2604-2612. PubMed ID: 33593884
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of KRAS G12V mutation in lung adenocarcinoma stratified by stages and radiological features.
Zhu W; Han H; Ma Z; Cao H; Yan Y; Zhao Y; Deng C; Xu H; Fu F; Fan F; Zhang Y; Chen H
J Thorac Cardiovasc Surg; 2024 Mar; ():. PubMed ID: 38527651
[TBL] [Abstract][Full Text] [Related]
10. Mesonephric-like adenocarcinoma of the female genital tract: possible role of KRAS-targeted treatment-detailed molecular analysis of a case series and review of the literature for targetable somatic KRAS-mutations.
Brambs CE; Horn LC; Hiller R; Krücken I; Braun C; Christmann C; Monecke A; Höhn AK
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15727-15736. PubMed ID: 37668797
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
